Adjuvant chemotherapy is not recommended to all patients with ER‐positive and HER2‐normal breast cancer but may in women with germline pathogenic BRCA1 or BRCA2 variants confer a distinct survival benefit 75, 78. This evidence concerns the gene ERBB2 and breast cancer.